Crescent Biopharma (CBIO)
Develops antibody medicines for solid tumors through bispecific and ADC programs.
$15.05
vs last close−1.39 (−8.45%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 78.52% | 29.16M shares | |
|---|---|---|---|
| 82 holders · as of Jun 30, 2026 | |||
| Insiders | 1.52% | 563.6K shares | |
| 8 holders · as of Sep 18, 2026 | |||
| Other | 19.96% | 7.42M shares | |
| remainder | |||
37.14M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
82 holders · 29.16M shares · 34 new positions · 51 increased · 14 reduced · 12 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 4.13M | 11.13% | 0 | Aug 13, 2026 |
| BVF Inc/IL | 2.75M | 7.40% | 0 | Aug 14, 2026 |
| Fairmount Funds Management LLC | 2.75M | 7.40% | 0 | Aug 14, 2026 |
| VR Adviser, LLC | 2.13M | 5.74% | 0 | Aug 14, 2026 |
| Logos Global Management LP | 1.90M | 5.12% | +1.42M | Aug 14, 2026 |
| FCPM Iii Services B.V. | 1.68M | 4.52% | 0 | Aug 14, 2026 |
| Balyasny Asset Management L.P. | 1.66M | 4.48% | +152.9K | Aug 14, 2026 |
| Vestal Point Capital, LP | 1.63M | 4.39% | +130.0K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Peter Harwinincl. Fairmount Funds Management LLC, Tomas Kiselak +1 more | 16.52% | 6.60M | 13D | Jul 20, 2026 |
| FMR LLC | 15.00% | 4.13M | 13G | Feb 5, 2026 |
| Arsani Williamincl. Logos Global Management LP, Logos Global Management GP LLC +2 more | 11.00% | 13G | Nov 27, 2024 | |
| 1Globe Capital LLC | 10.30% | 1.43M | 13G | Oct 14, 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 9.90% | 1.39M | 13G | Jun 23, 2025 |
| RA Capital Healthcare Fund, L.P.incl. Rajeev Shah, Peter Kolchinsky +1 more | 9.90% | 13G | Nov 6, 2024 | |
| ForGrowth III PA B.V. | 6.10% | 1.68M | 13G | Dec 11, 2025 |
| Balyasny Asset Management L.P. | 5.48% | 1.51M | 13G | May 15, 2026 |
| Vestal Point Capital, LP | 5.40% | 1.50M | 13G | Feb 17, 2026 |
| Biotechnology Value Fund L P | 5.10% | 707.1K | 13G | Aug 14, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 18, 2026 | Jonathan McNeillofficer: President and COO | Sale | 3,839 | $16.71 | 134,588 |
| Sep 16, 2026 | Jonathan McNeillofficer: President and COO | Sale | 731 | $17.90 | 138,427 |
| Sep 18, 2026 | Joshua T. Brummdirector, officer: Chief Executive Officer | Sale | 7,837 | $16.71 | 271,765 |
| Sep 16, 2026 | Joshua T. Brummdirector, officer: Chief Executive Officer | Sale | 1,610 | $17.90 | 279,602 |
| Sep 16, 2026 | Barbara Harlin Bisphamofficer: See Remarks | Sale | 620 | $17.90 | 18,710 |
| Sep 16, 2026 | Richard William Scalzoofficer: Chief Financial Officer | Sale | 568 | $17.90 | 19,730 |
| Sep 16, 2026 | Ellie Eunkyung Imofficer: Chief Medical Officer | Sale | 623 | $17.90 | 21,446 |
| Sep 16, 2026 | Jan Pinkasofficer: Chief Scientific Officer | Sale | 658 | $17.90 | 21,581 |
| Sep 16, 2026 | Ryan Lynchofficer: See Remarks | Sale | 240 | $17.90 | 13,631 |
| Jul 16, 2026 | Fairmount Funds Management LLCdirector, 10 percent owner: | Purchase · 2 lots | 1,379,347 | $8.97 | 5,895,353 |
House and Senate disclosures
Not reported.